Pacific Biosciences of California Cash Flow Conversion Efficiency

Latest as of June 2026: 2.417x

Pacific Biosciences of California cash flow conversion efficiency. Based on the latest financial reports, Pacific Biosciences of California (PACB) has a cash flow conversion efficiency ratio of 2.417x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-80.27 Million) by net assets ($-33.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Pacific Biosciences of California (2008–2025)

Cash flow conversion efficiency of Pacific Biosciences of California from 2008 to 2025. This chart illustrates how Pacific Biosciences of California's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pacific Biosciences of California share price for real-time trading data and today's change.

Pacific Biosciences of California Cash Flow Conversion Ratio Explained

Pacific Biosciences of California cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Pacific Biosciences of California Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pacific Biosciences of California ranked by their cash flow conversion efficiency. Also see Pacific Biosciences of California market cap and net worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Bassac
PA:BASS
-0.009x
Yuanli Chemical Group Co Ltd
SHG:603217
-0.001x
engcon AB Cl B
ST:ENGCON-B
0.079x
WAVE LIFE SCIENCES LTD.
F:1U5
-0.116x
Himalaya Shipping Ltd.
NYSE:HSHP
0.063x
Shanghai Xinpeng Industry Co Ltd
SHE:002328
0.059x
CRH PLC
LSE:CRH
-0.025x
Vina Concha To
SN:CONCHATORO
-0.032x

Annual Cash Flow Conversion Efficiency for Pacific Biosciences of California (2008–2025)

The table below shows the annual cash flow conversion efficiency of Pacific Biosciences of California from 2008 to 2025. Review Pacific Biosciences of California free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $5.35 Million $-111.21 Million -20.791x -5011.38%
2024-12-31 $506.59 Million $-206.06 Million -0.407x -7.02%
2023-12-31 $701.30 Million $-266.55 Million -0.380x +18.72%
2022-12-31 $562.90 Million $-263.21 Million -0.468x -232.67%
2021-12-31 $790.99 Million $-111.18 Million -0.141x -341.79%
2020-12-31 $335.49 Million $19.50 Million 0.058x +104.08%
2019-12-31 $54.92 Million $-78.31 Million -1.426x -144.85%
2018-12-31 $114.06 Million $-66.43 Million -0.582x +25.73%
2017-12-31 $86.10 Million $-67.52 Million -0.784x +2.26%
2016-12-31 $84.67 Million $-67.93 Million -0.802x -23.20%
2015-12-31 $73.54 Million $-47.89 Million -0.651x +30.48%
2014-12-31 $54.95 Million $-51.47 Million -0.937x -117.20%
2013-12-31 $69.18 Million $-29.83 Million -0.431x +38.60%
2012-12-31 $109.38 Million $-76.82 Million -0.702x -30.59%
2011-12-31 $191.46 Million $-102.97 Million -0.538x -23.38%
2010-12-31 $279.87 Million $-122.00 Million -0.436x -203.17%
2009-12-31 $-177.12 Million $-74.84 Million 0.423x +3.02%
2008-12-31 $-93.39 Million $-38.30 Million 0.410x --

About Pacific Biosciences of California

NASDAQ:PACB USA Medical Devices
Market Cap
$792.62 Million
Market Cap Rank
#10160 Global
#2746 in USA
Share Price
$2.55
Change (1 day)
+4.51%
52-Week Range
$1.11 - $2.90
All Time High
$51.15
About

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more